Sodium Glucose Co-Transporter 2 (SGLT2) 억제제
Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitor
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Sodium glucose co-transporter 2 (SGLT2) inhibition is a new therapeutic approach for the treatment of type 2 diabetes mellitus,independent of insulin secretion and activity. SGLT2 inhibitors have a unique mechanism of action via inhibition of renal glucosereabsorption, which is different from the mechanisms of prior medications. Clinical trials have supported the efficacy of SGLT2 inhibitorsin the reduction of HbA1c as monotherapy or add-on therapy with other existing medications, including insulin. In additionto their glucose-lowering effect, SGLT2 inhibitors can significantly reduce blood pressure and body weight. The most concerningside effects are genital and urinary tract infections, especially in females. SGLT2 inhibitors offer a promising potential strategy fordiabetes treatment because they can be combined with nearly any existing anti-diabetic medication, cause less hypoglycemia, andpossess additional metabolic benefits beyond glucose level reduction.
Abstract
Sodium glucose co-transporter 2 (SGLT2) inhibition is a new therapeutic approach for the treatment of type 2 diabetes mellitus,independent of insulin secretion and activity. SGLT2 inhibitors have a unique mechanism of action via inhibition of renal glucosereabsorption, which is different from the mechanisms of prior medications. Clinical trials have supported the efficacy of SGLT2 inhibitorsin the reduction of HbA1c as monotherapy or add-on therapy with other existing medications, including insulin. In additionto their glucose-lowering effect, SGLT2 inhibitors can significantly reduce blood pressure and body weight. The most concerningside effects are genital and urinary tract infections, especially in females. SGLT2 inhibitors offer a promising potential strategy fordiabetes treatment because they can be combined with nearly any existing anti-diabetic medication, cause less hypoglycemia, andpossess additional metabolic benefits beyond glucose level reduction.
참고문헌 (19)
- Korean Diabetes Association, "Diabetes Facts Sheets in Korea 2013", KDA, ~ (2013)
- Gerich JE, "Physiology of glucose homeostasis", Diabetes Obes Metab, 2, pp.345~350 (2000)
- Meyer C, "Role of human liver, kidney, and skeletal muscle in postprandial glucose homeostasis", Am J Physiol Endocrinol Metab, 282, pp.E419~427 (2002)
- Meyer C, "Relative importance of liver, kidney, and substrates in epinephrine-induced increased gluconeogenesis in humans", Am J Physiol Endocrinol Metab, 285, pp.E819~826 (2003)
- Bakris GL, "Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications", Kidney Int, 75, pp.1272~1277 (2009)
- Silverman M, "Handbook of Physiology", pp.2017~2038 (1992), Oxford University Press
- Nair S, "Sodium glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitus", J Clin Endocrinol Metab, 95, pp.34~42 (2010)
- Meyer C, "Abnormal renal, hepatic, and muscle glucose metabolism following glucose ingestion in type 2 diabetes", Am J Physiol Endocrinol Metab, 287, pp.E1049~1056 (2004)
- Vestri S, "Changes in sodium or glucose filtration rate modulate expression of glucose transporters in renal proximal tubular cells of rat", J Membr Biol, 182, pp.105~112 (2001)
- Freitas HS, "Na(+) -glucose transporter-2 messenger ribonucleic acid expression in kidney of diabetic rats correlates with glycemic levels: involvement of hepatocyte nuclear factor-1alpha expression and activity", Endocrinology, 149, pp.717~724 (2008)
- Rahmoune H, "Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with noninsulin- dependent diabetes", Diabetes, 54, pp.3427~3434 (2005)
- Kaku K, "Efficacy and safety of dapagliflozin as a monotherapy for type 2 diabetes mellitus in Japanese patients with inadequate glycaemic control: a phase II multicentre, randomized, double-blind, placebocontrolled trial", Diabetes Obes Metab, 15, pp.432~440 (2013)
- Bailey CJ, "Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial", Lancet, 375, pp.2223~2233 (2010)
- Nauck MA, "Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, activecontrolled noninferiority trial", Diabetes Care, 34, pp.2015~2022 (2011)
- Wilding JP, "A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment", Diabetes Care, 32, pp.1656~1662 (2009)
- Stenlof K, "Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise", Diabetes Obes Metab, 15, pp.372~382 (2013)
- Cefalu WT, "Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATASU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial", Lancet, 382, pp.941~950 (2013)
- Schernthaner G, "Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial", Diabetes Care, 36, pp.2508~2515 (2013)
- Yale JF, "Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease", Diabetes Obes Metab, 15, pp.463~473 (2013)